vaccine cancer (VAS) the most important feline health issue

Issues involving cat vaccines. Questions, answers, theories, and evidence.
Why do vaccines cause cancer in cats but not dogs or humans?

vaccine cancer (VAS) the most important feline health issue

Postby guest » Tue Sep 09, 2003 1:16 pm

Veterinary Cancer Society Newsletter Spring 2003

The Vaccine Associated Feline Sarcoma Task Force: Start to Premature Finish

Wallace Morrison DVM, DAVIM Purdue Univ. In

"The VAS Task Force was formed. as a joint response to what has clearly become the most important feline health issue since the recognition of FIV; induction of sarcomas following routine vaccination of cats.

The road to success of the Task Force has not been without difficulty. As you know, this is a politically charged issue. Compromise wording that shielded the vaccine industry from direct responsibility for creating this problem was required on most VASTF publications in order to keep the organization and funding intact. The response to the sarcoma problem by the vaccine companies has been passive and most seemingly took the position that their vaccines are safe or at least good enough for most cats. Development of non-sarcoma causing vaccines was never a stated goal of any company except Merial and no change in vaccine formulation or label recommendations was ever announced to VASTF in response to this problem. There was even a request to rename the VASTF, the Injection Site Associated Feline Sarcoma Task Force. Apparently to deflect attention away from the vaccine products that cause the overwhelming majority of disease (my personal preference for a new name was the Vaccine CAUSED Feline Sarcoma Task Force.) Sadly, a few in our own profession still have doubts about the whole issue and resent and resist any motive to modernize vaccine recommendations according to VASTF, AAFP, and AFM guidelines. Denial and inertia can be powerful enemies of progress.

In 2002 the Task Force recognized that funding was becoming harder to secure. For whatever reason (lack of real consequences for producing vaccines with catastrophic consequences for some cats, industry contributions to support research almost dried up.

Unfortunately, in late 2002 the AVMA declined to provide any additional funding for VAFTF. It is hard to imagine how the AVMA could see it in the interest of cats and their owners to walk away from this problem after having contributed substantially to the initial success f VAFSTF.

covering ulcerated vaccine tumors VAS tumors

Postby guest » Fri Jan 23, 2004 2:03 pm

this website may help show you how to keep inoperable vaccine tumors that are draining covered on your cat to protect the vaccine tumor from injury and gettting blood all over the house.

VAS enrollment in a study

Postby malernee » Thu Sep 30, 2004 9:45 am

Vaccine-Associated Feline Sarcoma

Dr. Jacqueline C. Whittemore

Post-vaccinal masses in cats: Help Wanted!

Drs. Dennis Macy and Jacqueline Whittemore at Colorado State University are currently seeking clinics for enrollment in a study regarding development of chronic post-vaccinal injection site reactions. This study is being funded through the Vaccine-Associated Feline Sarcoma Task Force.

The duration of post-vaccinal granulomas following vaccination with adjuvanted vaccines is not actually known. The fact that these granulomas cannot be easily differentiated from tumors that arise from vaccine sites has been troublesome. As one to 10 per 10,000 cats will develop a sarcoma at a site of rabies or FeLV vaccine administration, accurate assessment of post-vaccinal masses is very important. The Vaccine-Associated Feline Sarcoma Task Force’s (VAFSTF) guidelines for management of post-vaccinal local reactions were established based on clinical experience in the absence of systematic clinical evaluation of post-vaccinal granulomas. This study will determine the natural behavior of vaccine-associated granulomas and if current guidelines are appropriate or need to be modified.

We are seeking to recruit clinics for inclusion in the study. Each clinic would be responsible for vaccination of up to 48 cats routinely presented for vaccination with the specified rabies [Defensor (Pfizer Animal Health), Imrab 3 (Merial), and Rabvac 3 (Fort Dodge)] and/or FeLV vaccines [Leukocell 2 (Pfizer Animal Health) and Fel-O-Vax Lv-K (Fort Dodge)] within a 30 day period. One cat cannot be evaluated for more than one vaccine. Upon client enrollment, a one inch area of hair from the future vaccine injection site will be clipped and skin thickness measured prior to vaccination. Clients will be required to return for injection site evaluation every 21 days for up to 12 weeks post-vaccination. Should a mass develop that meets the VAFSTF guidelines for biopsy, it should be biopsied appropriately and submitted to us for analysis.

Veterinary clinics will receive $75 per cat, of which $25 will be remitted to the owner, after the PI has received the correctly completed official VAFSTF individual data sheets. The remaining $50 will be used to cover clinic costs. Veterinary clinics will receive $150 per case for surgical removal and submission of any injection site nodules requiring excision to the PI.

Please contact Dr. Whittemore for further information on this study by calling 970-297-4445 or emailing jacquiw(at)

Thank you for any assistance you may provide in this exciting study!

Clinical Trials and Research Projects
Clinical Trials/Research Projects
Canine Nasal Carcinoma
Cystitis, Feline
Diarrhea Clinical Study
Drug Toxicity
Epilepsy Research
Granulomatous Disease
Malignant Hyperthermia
Transdermal vs Oral Amitriptyline
Vaccine-associated granulomas

Date Published: July 6, 2004
Site Admin
Posts: 462
Joined: Wed Aug 13, 2003 5:56 pm

Return to Cat Vaccines

Who is online

Users browsing this forum: No registered users and 1 guest